Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
暂无分享,去创建一个
[1] John P. Overington,et al. Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.
[2] Jürgen Borlak,et al. Drug‐induced phospholipidosis , 2006, FEBS letters.
[3] Paul D. Leeson,et al. Reducing the Risk of Drug Attrition Associated with Physicochemical Properties , 2010 .
[4] Allan M Jordan,et al. The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates. , 2011, Journal of medicinal chemistry.
[5] David A. Price,et al. Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. , 2009, Bioorganic & medicinal chemistry letters.
[6] Yusuke Tsuda,et al. A practical use of ligand efficiency indices out of the fragment-based approach: ligand efficiency-guided lead identification of soluble epoxide hydrolase inhibitors. , 2011, Journal of medicinal chemistry.
[7] C. Humblet,et al. Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.
[8] Tudor I. Oprea,et al. Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..
[9] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[10] Jan Kelder,et al. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. , 2004, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[11] György G Ferenczy,et al. Thermodynamics guided lead discovery and optimization. , 2010, Drug discovery today.
[12] Tracey Clark,et al. Design of selective, ATP-competitive inhibitors of Akt. , 2010, Journal of medicinal chemistry.
[13] W. Curatolo,et al. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings , 1998 .
[14] J. Gasteiger,et al. Prediction of Aqueous Solubility of Organic Compounds by Topological Descriptors , 2003 .
[15] Brett A Tounge,et al. Ligand efficiency and fragment-based drug discovery. , 2009, Drug discovery today.
[16] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[17] Bruce D. Hammock,et al. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases , 2009, Nature Reviews Drug Discovery.
[18] A. Hill,et al. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. , 2010, Drug discovery today.
[19] E. Freire. Do enthalpy and entropy distinguish first in class from best in class? , 2008, Drug discovery today.
[20] Stephen D Pickett,et al. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. , 2011, Drug discovery today.
[21] L. Amzel,et al. Compensating Enthalpic and Entropic Changes Hinder Binding Affinity Optimization , 2007, Chemical biology & drug design.
[22] Tudor I. Oprea,et al. The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.
[23] J. T. Metz,et al. Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.
[24] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[25] Gerhard Klebe,et al. Adding calorimetric data to decision making in lead discovery: a hot tip , 2010, Nature Reviews Drug Discovery.
[26] J. Lyons,et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines , 2009, Molecular Cancer Therapeutics.
[27] T. Ritchie,et al. The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.
[28] M. Wendt. Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein–protein interaction , 2008, Expert opinion on drug discovery.
[29] J. Peters,et al. Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.
[30] A. Velázquez‐Campoy,et al. Thermodynamic dissection of the binding energetics of KNI‐272, a potent HIV‐1 protease inhibitor , 2000, Protein science : a publication of the Protein Society.
[31] Nigel Greene,et al. Evaluation of a Published in Silico Model and Construction of a Novel Bayesian Model for Predicting Phospholipidosis Inducing Potential , 2007, J. Chem. Inf. Model..
[32] S. Bembenek,et al. Ligand binding efficiency: trends, physical basis, and implications. , 2008, Journal of medicinal chemistry.
[33] P. Kinnunen,et al. Screening for the Drug–Phospholipid Interaction: Correlation to Phospholipidosis , 2009, ChemMedChem.
[34] Paul D. Leeson,et al. Impact of ion class and time on oral drug molecular properties , 2011 .
[35] C. Abad-Zapatero,et al. Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.
[36] M. Holloway,et al. Thermodynamics of ligand binding and efficiency. , 2011, ACS medicinal chemistry letters.
[37] J. Lange,et al. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. , 2010, Bioorganic & medicinal chemistry letters.
[38] M. Waring,et al. A quantitative assessment of hERG liability as a function of lipophilicity. , 2007, Bioorganic & medicinal chemistry letters.
[39] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[40] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[41] E. Freire,et al. A Thermodynamic Approach to the Affinity Optimization of Drug Candidates , 2009, Chemical biology & drug design.
[42] Kiyohiko Sugano,et al. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. , 2006, The Journal of toxicological sciences.
[43] Hongyu Zhao. Lead optimization in the nondrug-like space. , 2011, Drug discovery today.
[44] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[45] Alexander Alex,et al. Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space , 2011 .
[46] Dafydd R Owen,et al. Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis. , 2009, Bioorganic & medicinal chemistry letters.
[47] T. J. Nitz,et al. Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. , 1995, Journal of medicinal chemistry.
[48] P. Clemons,et al. Distinct Biological Network Properties between the Targets of Natural Products and Disease Genes , 2010, Journal of the American Chemical Society.
[49] R Scott Obach,et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. , 2010, Journal of medicinal chemistry.
[50] H. Moser,et al. Physicochemical properties of antibacterial compounds: implications for drug discovery. , 2008, Journal of medicinal chemistry.
[51] Paul D Leeson,et al. Time-related differences in the physical property profiles of oral drugs. , 2004, Journal of medicinal chemistry.
[52] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[53] D. Knighton,et al. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design , 2010 .
[54] S. Hitchcock,et al. Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.
[55] Peter Ertl,et al. The graphical representation of ADME-related molecule properties for medicinal chemists. , 2011, Drug discovery today.
[56] G. Holdgate,et al. Measurements of binding thermodynamics in drug discovery. , 2005, Drug discovery today.
[57] Li Xing,et al. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. , 2004, Journal of medicinal chemistry.
[58] György G. Ferenczy,et al. Enthalpic Efficiency of Ligand Binding , 2010, J. Chem. Inf. Model..
[59] A. Ratcliffe,et al. Medicinal chemistry strategies to minimize phospholipidosis. , 2009, Current medicinal chemistry.
[60] A. Wood,et al. Pyrazole NNRTIs 3: optimisation of physicochemical properties. , 2009, Bioorganic & medicinal chemistry letters.
[61] A. Bender,et al. Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.
[62] M. Waring. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. , 2009, Bioorganic & medicinal chemistry letters.
[63] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[64] I. Kuntz,et al. The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[65] Marta Bellini,et al. Straightforward recursive partitioning model for discarding insoluble compounds in the drug discovery process. , 2008, Journal of medicinal chemistry.
[66] J. Proudfoot. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. , 2002, Bioorganic & medicinal chemistry letters.
[67] E. Freire,et al. Binding thermodynamics of statins to HMG-CoA reductase. , 2005, Biochemistry.
[68] Z. Rankovic,et al. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.
[69] Graham F. Smith. Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design. , 2009, Progress in medicinal chemistry.
[70] M. Edwards,et al. Using the Golden Triangle to optimize clearance and oral absorption. , 2009, Bioorganic & medicinal chemistry letters.
[71] Tudor I. Oprea,et al. Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.
[72] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[73] J. Hughes,et al. Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.
[74] Emanuele Perola,et al. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. , 2010, Journal of medicinal chemistry.
[75] Min Gao,et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect , 2010, Nature.
[76] Marcel L Verdonk,et al. Identification of inhibitors of protein kinase B using fragment-based lead discovery. , 2007, Journal of medicinal chemistry.
[77] P. Leeson,et al. A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.
[78] Inhibitors of sterol synthesis: 3 beta-hydroxy-25,26,26,26,27,27,27- heptafluoro-5 alpha-cholestan-15-one, an analog of a potent hypocholesterolemic agent in which its major metabolism is blocked. , 1994, Biochemical and biophysical research communications.
[79] M. Hann. Molecular obesity, potency and other addictions in drug discovery , 2011 .
[80] Sheng Tian,et al. ADME evaluation in drug discovery. 9. Prediction of oral bioavailability in humans based on molecular properties and structural fingerprints. , 2011, Molecular pharmaceutics.
[81] Paul G Wyatt,et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.
[82] P. Verhoest,et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. , 2010, ACS chemical neuroscience.
[83] Stuart L. Schreiber,et al. Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles , 2010, Proceedings of the National Academy of Sciences.
[84] Ian A. Watson,et al. Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.
[85] N. Kitteringham,et al. Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications. , 1994, Drug metabolism reviews.
[86] B. Kuhn,et al. Intramolecular hydrogen bonding in medicinal chemistry. , 2010, Journal of medicinal chemistry.
[87] Hisashi Shinkai,et al. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents , 2009, Expert opinion on therapeutic patents.
[88] J. Corradi,et al. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. , 2010, Chemical research in toxicology.
[89] Brett A Tounge,et al. The role of molecular size in ligand efficiency. , 2007, Bioorganic & medicinal chemistry letters.
[90] J. Proudfoot,et al. The evolution of synthetic oral drug properties. , 2005, Bioorganic & medicinal chemistry letters.
[91] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[92] J. Willem M. Nissink,et al. Simple Size-Independent Measure of Ligand Efficiency , 2009, J. Chem. Inf. Model..
[93] Marcel L Verdonk,et al. Group Efficiency: A Guideline for Hits‐to‐Leads Chemistry , 2008, ChemMedChem.
[94] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[95] Lawrence X. Yu,et al. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. , 2006, Molecular pharmaceutics.
[96] E. Freire,et al. Isothermal titration calorimetry: controlling binding forces in lead optimization. , 2004, Drug discovery today. Technologies.
[97] P. Verhoest,et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.
[98] Pravin Chaturvedi,et al. Design principles for orally bioavailable drugs , 1996 .